{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:53Z","timestamp":1787020133439,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hubei Chen Xiaoping Science and Technology Development Foundation","award":["CXPJJH121001-2021074"],"award-info":[{"award-number":["CXPJJH121001-2021074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Advanced gastric cancer (AGC) with unresectable factors presents a significant treatment challenge. Conventional treatments such as systemic chemotherapy, radiotherapy, and immunotherapy can delay disease progression but often yield limited outcomes. For stage III-IV gastric cancer with unresectable factors, conversion therapy based on chemotherapy can achieve tumor downstaging, providing a subset of patients with the opportunity for curative surgery. However, the efficacy of multimodal approaches combining chemotherapy, with or without immunotherapy, and conversion surgery compared to chemotherapy alone remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of high-quality studies published between January 2014 and November 2024, assessing the role of surgery following conversion therapy in advanced gastric cancer. Relevant studies were retrieved from PubMed, Embase, and Web of Science databases. All included studies were observational; no randomized trials were available. Clinical data, including overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse event (AE) rates, were analyzed using RevMan 5.4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twelve observational cohort studies were included. Conversion surgery(CS) was associated with improved 1-year, 3-year, and 5-year OS rates (RR 0.38, 95% CI: 0.31\u20130.47; RR 0.64, 95% CI: 0.54\u20130.76; RR 0.77, 95% CI: 0.65\u20130.91, respectively) and increased 1-year and 3-year PFS rates (RR 0.57, 95% CI: 0.49\u20130.99; RR 0.67, 95% CI: 0.57\u20130.78, respectively). No significant difference in AE rates was observed between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Conversion surgery following chemotherapy in stage III-IV gastric cancer is associated with improved OS and PFS in observational studies. However, these findings may reflect inherent prognostic differences between groups, as surgery was only feasible for chemotherapy responders. Prospective trials are needed to validate causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-03969-x","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:53:59Z","timestamp":1747209239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiaheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuetian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulin","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"3","key":"3969_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"3969_CR2","doi-asserted-by":"publisher","first-page":"115080","DOI":"10.1016\/j.ejca.2024.115080","volume":"213","author":"K Fujitani","year":"2024","unstructured":"Fujitani K, Kurokawa Y, Wada R, Takeno A, Kawabata R, Omori T, Imamura H, Hirao M, Endo S, Kawada J, et al. Prospective single-arm multicenter interventional study of surgical resection for liver metastasis from gastric cancer; 3-year overall and recurrence-free survival. Eur J Cancer. 2024;213:115080. https:\/\/doi.org\/10.1016\/j.ejca.2024.115080.","journal-title":"Eur J Cancer"},{"issue":"12","key":"3969_CR3","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/s1470-2045(24)00580-1","volume":"25","author":"G Randon","year":"2024","unstructured":"Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, et al. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25(12):1539\u201350. https:\/\/doi.org\/10.1016\/s1470-2045(24)00580-1.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3969_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s10120-024-01516-3","volume":"27","author":"YK Kang","year":"2024","unstructured":"Kang YK, Qin S, Lee KW, Oh SC, Kim IH, Kim JG, Li Y, Yan Z, Li J, Bai LY, et al. Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric\/gastroesophageal junction cancer: subgroup of FIGHT final analysis. Gastric Cancer. 2024;27(5):1046\u201357. https:\/\/doi.org\/10.1007\/s10120-024-01516-3.","journal-title":"Gastric Cancer"},{"issue":"7","key":"3969_CR5","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41591-024-03007-5","volume":"30","author":"X Gao","year":"2024","unstructured":"Gao X, Ji K, Jia Y, Shan F, Chen Y, Xu N, Jia Z, Liu T, Yang N, Zhong H, et al. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b\/2 COMPASSION-04 trial. Nat Med. 2024;30(7):1943\u201351. https:\/\/doi.org\/10.1038\/s41591-024-03007-5.","journal-title":"Nat Med"},{"issue":"10458","key":"3969_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/s0140-6736(24)01595-2","volume":"404","author":"R Adam","year":"2024","unstructured":"Adam R, Piedvache C, Chiche L, Adam JP, Salam\u00e9 E, Bucur P, Cherqui D, Scatton O, Granger V, Ducreux M, et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. Lancet. 2024;404(10458):1107\u201318. https:\/\/doi.org\/10.1016\/s0140-6736(24)01595-2.","journal-title":"Lancet"},{"issue":"8","key":"3969_CR7","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00432-021-03516-7","volume":"147","author":"H Ohnuma","year":"2021","unstructured":"Ohnuma H, Sato Y, Onoyama N, Hamaguchi K, Hayasaka N, Sato M, Murase K, Takada K, Miyanishi K, Murakami T, et al. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. J Cancer Res Clin Oncol. 2021;147(8):2385\u201396. https:\/\/doi.org\/10.1007\/s00432-021-03516-7.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"3969_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10120-016-0633-1","volume":"20","author":"Y Sato","year":"2017","unstructured":"Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer. 2017;20(3):517\u201326. https:\/\/doi.org\/10.1007\/s10120-016-0633-1.","journal-title":"Gastric Cancer"},{"issue":"6","key":"3969_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000328197","volume":"78","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Osada S, Takahashi T, Tanaka Y, Tanabe K, Suzuki T. The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology. 2011;78(6):343\u201352. https:\/\/doi.org\/10.1159\/000328197.","journal-title":"Pathobiology"},{"issue":"9","key":"3969_CR10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.ejca.2014.02.024","volume":"50","author":"RP Jones","year":"2014","unstructured":"Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer. 2014;50(9):1590\u2013601. https:\/\/doi.org\/10.1016\/j.ejca.2014.02.024.","journal-title":"Eur J Cancer"},{"issue":"3_SUPPL","key":"3969_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1200\/JCO.2024.42.3_suppl.281","volume":"42","author":"H Liang","year":"2024","unstructured":"Liang H, Li F, Zhang H, Xie Q, Zhong R, Huang K, Yan X, Li Z, Huang Z, Hu Y, et al. Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer with peritoneal metastasis. Journal of Clinical Oncology. 2024;42(3_SUPPL):281\u2013281. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.281.","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"3969_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1159\/000509530","volume":"98","author":"T Arigami","year":"2020","unstructured":"Arigami T, Matsushita D, Okubo K, Sasaki K, Noda M, Kita Y, Mori S, Kurahara H, Yanagita S, Uenosono Y, et al. Clinical Significance of Conversion Surgery for Gastric Cancer with Peritoneal Dissemination: A Retrospective Study. Oncology. 2020;98(11):798\u2013806. https:\/\/doi.org\/10.1159\/000509530.","journal-title":"Oncology"},{"key":"3969_CR13","doi-asserted-by":"publisher","unstructured":"Shin MK, Choi MG, Kim ST, Kang WK, Sohn TS, An JY, Lee JH, Lee JY: The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy. Biomedicines 2023, 11(11). https:\/\/doi.org\/10.3390\/biomedicines11113097.","DOI":"10.3390\/biomedicines11113097"},{"issue":"2","key":"3969_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10120-017-0738-1","volume":"21","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, Tanabe K, Ohdan H. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2018;21(2):315\u201323. https:\/\/doi.org\/10.1007\/s10120-017-0738-1.","journal-title":"Gastric Cancer"},{"key":"3969_CR15","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.annonc.2023.04.232","volume":"34","author":"H Liang","year":"2023","unstructured":"Liang H, Yan X, Li F, Li Z, Qiu Y, Feng H, Zhang R, Liu H, Li G, Zhao L. Survival benefits of conversion surgery for stage IV gastric cancer patients treated with anti-PD-1 antibody and chemotherapy and\/or targeted therapy. Annals of Oncology. 2023;34:S78. https:\/\/doi.org\/10.1016\/j.annonc.2023.04.232.","journal-title":"Annals of Oncology"},{"issue":"3","key":"3969_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00423-021-02410-7","volume":"407","author":"M Shinkai","year":"2022","unstructured":"Shinkai M, Imano M, Hiraki Y, Momose K, Kato H, Shiraishi O, Yasuda A, Tsubaki M, Nishida S, Yasuda T. Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis. Langenbecks Archives of Surgery. 2022;407(3):975\u201383. https:\/\/doi.org\/10.1007\/s00423-021-02410-7.","journal-title":"Langenbecks Archives of Surgery"},{"key":"3969_CR17","doi-asserted-by":"publisher","unstructured":"Huang R-Y, Kou H-W, Le P-H, Kuo C-J, Chen T-H, Wang S-Y, Chen J-S, Yeh T-S, Hsu J-T: Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone. Journal of Personalized Medicine 2022;12(4). https:\/\/doi.org\/10.3390\/jpm12040555.","DOI":"10.3390\/jpm12040555"},{"issue":"1","key":"3969_CR18","first-page":"211","volume":"26","author":"Y Li","year":"2021","unstructured":"Li Y, Lin H, Huang K, Zhao J. Efficacy of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy in treating peritoneal metastasis of gastric cancer. J BUON. 2021;26(1):211\u20137.","journal-title":"J BUON"},{"issue":"11","key":"3969_CR19","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.21873\/anticanres.13010","volume":"38","author":"M Fukuchi","year":"2018","unstructured":"Fukuchi M, Mochiki E, Ishiguro T, Kumagai Y, Ishibashi K, Ishida H. Prognostic Significance of Conversion Surgery Following First- or Second-line Chemotherapy for Unresectable Gastric Cancer. Anticancer research. 2018;38(11):6473\u20138. https:\/\/doi.org\/10.21873\/anticanres.13010.","journal-title":"Anticancer research"},{"key":"3969_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12957-016-0790-z","volume":"14","author":"N Yamada","year":"2016","unstructured":"Yamada N, Akai A, Nomura Y, Tanaka N. The impact and optimal indication of non-curative gastric resection for stage IV advanced gastric cancer diagnosed during surgery: 10 years of experience at a single institute. World J Surg Oncol. 2016;14:79. https:\/\/doi.org\/10.1186\/s12957-016-0790-z.","journal-title":"World J Surg Oncol"},{"key":"3969_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12957-015-0627-1","volume":"13","author":"Z Li","year":"2015","unstructured":"Li Z, Fan B, Shan F, Tang L, Bu Z, Wu A, Zhang L, Wu X, Zong X, Li S, et al. Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study. World J Surg Oncol. 2015;13:212. https:\/\/doi.org\/10.1186\/s12957-015-0627-1.","journal-title":"World J Surg Oncol"},{"issue":"10","key":"3969_CR22","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ejso.2015.04.021","volume":"41","author":"J Kinoshita","year":"2015","unstructured":"Kinoshita J, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I, Nakamura K, Miyashita T, Tajima H, Takamura H, et al. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol. 2015;41(10):1354\u201360. https:\/\/doi.org\/10.1016\/j.ejso.2015.04.021.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"3969_CR23","first-page":"401","volume":"35","author":"S Ito","year":"2015","unstructured":"Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi Y, Ohgaki K, Saeki H, Morita M, Sakaguchi Y, Maehara Y. Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Res. 2015;35(1):401\u20136.","journal-title":"Anticancer Res"},{"issue":"11","key":"3969_CR24","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1245\/s10434-015-4422-6","volume":"22","author":"M Fukuchi","year":"2015","unstructured":"Fukuchi M, Ishiguro T, Ogata K, Suzuki O, Kumagai Y, Ishibashi K, Ishida H, Kuwano H, Mochiki E. Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer. Ann Surg Oncol. 2015;22(11):3618\u201324. https:\/\/doi.org\/10.1245\/s10434-015-4422-6.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"3969_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00280-014-2449-1","volume":"73","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yu Y-Y, Li W, Feng Y, Hou J, Ji Y, Sun Y-H, Shen K-T, Shen Z-B, Qin X-Y, et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemotherapy and Pharmacology. 2014;73(6):1155\u201361. https:\/\/doi.org\/10.1007\/s00280-014-2449-1.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"10","key":"3969_CR26","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00595-024-02829-7","volume":"54","author":"F Chen","year":"2024","unstructured":"Chen F, Xian J, Huo J. Prognostic significance of a pathological response in metastatic lymph nodes of patients with gastric cancer who underwent neoadjuvant chemotherapy followed by surgery. Surgery Today. 2024;54(10):1255\u201364. https:\/\/doi.org\/10.1007\/s00595-024-02829-7.","journal-title":"Surgery Today"},{"key":"3969_CR27","doi-asserted-by":"publisher","unstructured":"Araruna GF, Ribeiro HSC, Torres SM, Diniz AL, Godoy AL, Farias IC, Costa WL, Coimbra FJF: Impact of Minimally Invasive Surgery on Early and Late Outcomes of Patients With Gastric Cancer Treated Using Neoadjuvant Chemotherapy. Journal of Surgical Oncology 2024.\nhttps:\/\/doi.org\/10.1002\/jso.27904.","DOI":"10.1002\/jso.27904"},{"issue":"5","key":"3969_CR28","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.21873\/anticanres.16383","volume":"43","author":"K Morino","year":"2023","unstructured":"Morino K, Yamamoto M, Yamanaka R, Iwasaki Y, Nakanishi N, Goto T, Tanaka H, Matsusue R, Machimoto T. Clinical Impact of Laparoscopic Surgery on the Long-term Survival of Advanced Gastric Cancer Patients With Regard to Facilitating Doublet Adjuvant Chemotherapy. Anticancer Research. 2023;43(5):2203\u20139. https:\/\/doi.org\/10.21873\/anticanres.16383.","journal-title":"Anticancer Research"},{"issue":"25","key":"3969_CR29","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1097\/md.0000000000000164","volume":"93","author":"H Liu","year":"2014","unstructured":"Liu H, Chen X, Sun J, Gao P, Song Y, Zhang N, Lu X, Xu H, Wang Z. The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014;93(25):e164. https:\/\/doi.org\/10.1097\/md.0000000000000164.","journal-title":"Medicine (Baltimore)"},{"issue":"9813","key":"3969_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/s0140-6736(11)61873-4","volume":"379","author":"YJ Bang","year":"2012","unstructured":"Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315\u201321. https:\/\/doi.org\/10.1016\/s0140-6736(11)61873-4.","journal-title":"Lancet"},{"issue":"1","key":"3969_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10120-021-01224-2","volume":"25","author":"Y Kakeji","year":"2022","unstructured":"Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, et al. Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07. Gastric Cancer. 2022;25(1):188\u201396. https:\/\/doi.org\/10.1007\/s10120-021-01224-2.","journal-title":"Gastric Cancer"},{"issue":"2","key":"3969_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.12809\/hkjr2317576","volume":"26","author":"TCY So","year":"2023","unstructured":"So TCY, Lee KC, Wong ECY. Treatment Outcomes of Stage II or III Gastric Cancer Treated with Adjuvant Chemotherapy with TS-1 or XELOX after Radical Surgery. Hong Kong Journal of Radiology. 2023;26(2):91\u20139. https:\/\/doi.org\/10.12809\/hkjr2317576.","journal-title":"Hong Kong Journal of Radiology"},{"issue":"3","key":"3969_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(15)00553-7.","journal-title":"Lancet Oncol"},{"issue":"9","key":"3969_CR34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"SE Al-Batran","year":"2017","unstructured":"Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017;3(9):1237\u201344. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0515.","journal-title":"JAMA Oncol"},{"issue":"2","key":"3969_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3760\/cma.j.cn.441530-20201215-00661","volume":"24","author":"H Liang","year":"2021","unstructured":"Liang H. Progress in conversion therapy for stage IV gastric cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2021;24(2):107\u201311. https:\/\/doi.org\/10.3760\/cma.j.cn.441530-20201215-00661.","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"issue":"1","key":"3969_CR36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1245\/s10434-019-07697-x","volume":"27","author":"T Yamaguchi","year":"2020","unstructured":"Yamaguchi T, Takashima A, Nagashima K, Makuuchi R, Aizawa M, Ohashi M, Tashiro K, Yamada T, Kinoshita T, Hata H, et al. Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study. Ann Surg Oncol. 2020;27(1):284\u201392. https:\/\/doi.org\/10.1245\/s10434-019-07697-x.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"3969_CR37","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.ejso.2016.03.030","volume":"42","author":"GA Tiberio","year":"2016","unstructured":"Tiberio GA, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C, Graziosi L, Pedrazzani C, Baiocchi GL, La Barba G, et al. Factors influencing survival after hepatectomy for metastases from gastric cancer. Eur J Surg Oncol. 2016;42(8):1229\u201335. https:\/\/doi.org\/10.1016\/j.ejso.2016.03.030.","journal-title":"Eur J Surg Oncol"},{"key":"3969_CR38","doi-asserted-by":"publisher","unstructured":"Zhai Y, Zheng Z, Deng W, Yin J, Bai Z, Liu X, Zhang J, Zhang Z: Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis. Frontiers in Surgery 2023;9.\nhttps:\/\/doi.org\/10.3389\/fsurg.2022.1047456.","DOI":"10.3389\/fsurg.2022.1047456"},{"key":"3969_CR39","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.2147\/cmar.S203880","volume":"11","author":"L Wu","year":"2019","unstructured":"Wu L, Ge L, Qin Y, Huang M, Chen J, Yang Y, Zhong J. Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis. Cancer Management and Research. 2019;11:6011\u20138. https:\/\/doi.org\/10.2147\/cmar.S203880.","journal-title":"Cancer Management and Research"},{"key":"3969_CR40","doi-asserted-by":"publisher","unstructured":"Nakazawa N, Sohda M, Hosoi N, Watanabe T, Kumakura Y, Yamashita T, Tanaka N, Saito K, Kimura A, Kasuga K et al: Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study. Annals of Surgical Oncology 2024. https:\/\/doi.org\/10.1245\/s10434-024-16161-4.","DOI":"10.1245\/s10434-024-16161-4"},{"issue":"11","key":"3969_CR41","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00595-021-02320-7","volume":"51","author":"T Arigami","year":"2021","unstructured":"Arigami T, Matsushita D, Okubo K, Sasaki K, Noda M, Kita Y, Mori S, Kurahara H, Yanagita S, Uenosono Y, et al. Prognostic impact of surgery after chemotherapy for type 4 gastric cancer. Surgery Today. 2021;51(11):1851\u20139. https:\/\/doi.org\/10.1007\/s00595-021-02320-7.","journal-title":"Surgery Today"},{"key":"3969_CR42","doi-asserted-by":"publisher","first-page":"S905","DOI":"10.1016\/j.annonc.2020.08.1940","volume":"31","author":"J Zhang","year":"2020","unstructured":"Zhang J, Yang D, Zhao Q, Zhang HW, Zheng ZC. A prospective, multicenter, non-randomized, controlled trial of apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer. Annals of Oncology. 2020;31:S905. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1940.","journal-title":"Annals of Oncology"},{"issue":"6","key":"3969_CR43","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1245\/s10434-021-11203-7","volume":"29","author":"M Nishi","year":"2022","unstructured":"Nishi M, Shimada M, Yoshikawa K, Takasu C, Wada Y, Tokunaga T, Nakao T, Kashihara H, Yoshimoto T, Yamashita S. Propensity Score-Matched Analysis of the Short- and Long-Term Outcomes of Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer. Ann Surg Oncol. 2022;29(6):3887\u201395. https:\/\/doi.org\/10.1245\/s10434-021-11203-7.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"3969_CR44","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/bjs.11702","volume":"107","author":"M Ri","year":"2020","unstructured":"Ri M, Nunobe S, Honda M, Akimoto E, Kinoshita T, Hori S, Aizawa M, Yabusaki H, Isobe Y, Kawakubo H, et al. Gastrectomy with or without omentectomy for cT3\u20134 gastric cancer: a multicentre cohort study. Br J Surg. 2020;107(12):1640\u20137. https:\/\/doi.org\/10.1002\/bjs.11702.","journal-title":"Br J Surg"},{"issue":"2","key":"3969_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/sla.0000000000001814","volume":"265","author":"T Sano","year":"2017","unstructured":"Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017;265(2):277\u201383. https:\/\/doi.org\/10.1097\/sla.0000000000001814.","journal-title":"Ann Surg"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03969-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03969-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:54:00Z","timestamp":1747209240000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03969-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3969"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03969-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a systematic review and meta-analysis, our study did not require any human participation and, referral to our ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}